![]() Stockwatch: two coronavirus stocks where momentum favours the brave.Insider: bosses make fortunes backing Covid-19 winners.Novacyt: cash pile builds amid Covid sales boom.It is also reaping benefits from having a much bigger base of global customers for its wider portfolio of diagnostic products. In the meantime, the low capital intensity of its manufacturing process means Novacyt is generating significant levels of cash. ![]() The recent share price decline comes amid signs the coronavirus is losing its potency in many European countries, as well as the possibility a vaccine will reduce demand for such tests. Past performance is not a guide to future performance. They include one for use by labs involved in performing high volumes of tests. They've recovered a little since then and were up as much as 15% to 276p today after Novacyt disclosed the launch of three new products to support laboratories testing for Covid-19. More recent buyers, however, have been left disappointed as the stock slipped back to just above the 200p mark at the start of this week. The shares peaked at 529p on 16 April, meaning investors who bought back in late January when Novacyt first disclosed its testing progress would have been sitting on a profit of more than 3,000%. ![]() Novacyt (LSE:NCYT) has been the hottest stock on AIM during the junior market's 25th year, with the company's success in developing Covid-19 testing tools propelling it from relative obscurity to the top 10 list of most-popular shares on the interactive investor platform. The latest round of updates brought disappointment for holders of shares in advertising technology business Tremor International (LSE:TRMR) - known as Taptica until last year - and robotic software provider Blue Prism, which fell 8% after half-year results.īut there were further gains for Berkeley Energia (LSE:BKY), despite the company behind a uranium mining project in Spain seeing no reason for its shares soaring 70% this week alone. Novacyt (LSE:NCYT) and Safestore (LSE:SAFE) re-energised their faltering share prices today during a mixed session for followers of AIM-listed ten-baggers, and other high-flyers past and present. A Covid winner, old favourites and star stocks feature in today’s analysis, plus a 330% gain for one. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |